{
  "docId": "019de075-4aec-72cf-a6e0-519f4b0af11c",
  "docSlug": "80e6ab6db3df4d91b63f99a2a4cf6dc3",
  "documentTitle": "Exscientia | Investor Presentation Deck | 73 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 70,
  "pageCount": 73,
  "prevPage": 69,
  "nextPage": 71,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "The chart shows tumor volume over time (D20-D30) for various treatment groups, highlighting the superior performance of the combination therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4aec-72cf-a6e0-519f4b0af11c/70",
  "deckHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c",
  "deckJsonHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c.json",
  "deckAnchorHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c#slide-70",
  "components": [
    {
      "bbox": {
        "h": 0.479,
        "w": 0.446,
        "x": 0.487,
        "y": 0.239
      },
      "kind": "chart",
      "text": "Tumour Volume (mean +/- SD) Data from Combination Ibrutinib Study",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9575a25e-58bf-4ec0-987d-ac7a4aab0f8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.07,
        "y": 0.025
      },
      "kind": "list",
      "text": "TMD8 DLBCL cells are sensitive to both MALT1 and ibrutinib in vitro\nHowever, administration of ibrutinib or '565 (30 mg/kg BID) showed no activity in the TMD8 model in vivo when administered alone\nNotably, significant synergistic efficacy was observed when '565 was combined with ibrutinib in the study\n'565 was well tolerated with body weight maintained in both monotherapy and combination groups",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec412a6c-8951-4cd4-a913-a1568e3811b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Synergistic efficacy of '565 in combination with ibrutinib",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "343f8b02-b774-4bc3-9c26-5c6d7b33f233",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "'565 deepens response to ibrutinib in vivo",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0df0e56b-48fd-427c-bfc4-a964e6fd5478",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "2cbe71fd-9cbe-4434-ba9b-4c1b1f932b77",
      "evidence": "chart/line: Tumour Volume (mean +/- SD) Data from Combination Ibrutinib Study",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 73,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "02ebf716-8af1-4eca-8937-1321b5d2471c",
      "evidence": "The deck presents the consequences of not adopting Exscientia's technology throughout the presentation",
      "position": 0,
      "objective": "What is the cost of not adopting Exscientia's AI-driven precision medicine platform?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 72,
      "from": 29,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c1ff2e13-046f-4a68-9f90-d544bd3e6de9",
      "evidence": "The deck presents information on Exscientia's clinical stage compounds and their potential benefits",
      "position": 1,
      "objective": "What are the potential benefits of Exscientia's clinical stage compounds?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}